盐酸埃克替尼治疗晚期非小细胞肺癌的临床疗效观察

Efficacy of icotinib hydrochloride in the treatment of advanced nonsmall cell lung cancer

目的观察和评价盐酸埃克替尼用于治疗晚期非小细胞肺癌（NSCLC）的疗效及不良反应，分析其影响疗效和预后的相关因素。方法统计在江苏省肿瘤医院慈善赠药点服用盐酸埃克替尼治疗的260例晚期NSCLC患者的临床资料进行回顾性分析。结果260例患者中有4例因不良反应不能耐受而停药，可评价近期疗效的患者为256例，首次服药4周后进行疗效评价。可评价疗效的256例患者中，完全缓解0例，部分缓解96例（37．5％），疾病稳定97例（37．9％），疾病进展63例（24．6％）。客观缓解率为37．6％，疾病控制率为75．4％，260例患者中位无进展生存期为7（0．4～16．3）个月。一线、二线、三线及三线以上治疗患者中位无进展生存期分别为11（1～16．3）、6（0．4～11．3）、5（1～13．5）个月。结论盐酸埃克替尼治疗晚期NSCLC具有显著的疗效和良好的安全性。

Objective To observe and evaluate the efficiency and adverse reactions of icotinib hydrochloride in the treatment of advanced non-small cell lung cancer （NSCLC）, and analyze the relative factors affecting its efficiency and prognosis. Methods The clinical data of 260 patients with advanced NSCLC treated with icotinib hydrochloride in Jiangsu Cancer Hospital was retrospectively analyzed. Results 4 weeks after initially taking medicine, 256 patients were evaluable for efficacy except 4 patients stopped taking the medicine due to intolerable adverse reactions. Among 256 patients, there was none with complete response （CR）, 96 with partial response （PR, 37.5%）, 97 with stable disease （SD, 37.9%） and 63 with progression disease （PD, 24.6%）. The objective remission rate was 37.6%, and disease control rate was 75.4%. Among 260 patients, the median progression-free survival （PFS） was 7 （0.4 - 16.3） months, and those of those treated with first-line, second-line, third-line treatment and above were 11 （1 - 16.3）, 6（0.4 - 11.3） and 5 （1 - 13.5） months, respectively. Conclusion Icotinib hydrochloride for treating advanced NSCLC has significant efficiency and better safety.